NO326523B1 - CD19xCD3-spesifikke polypeptid, vektor, celle, sammensetning, fremgangsmate for fremstilling samt anvendelse av nevnte polypeptid eller et polynukleotid som koder for nevnte polypeptid. - Google Patents

CD19xCD3-spesifikke polypeptid, vektor, celle, sammensetning, fremgangsmate for fremstilling samt anvendelse av nevnte polypeptid eller et polynukleotid som koder for nevnte polypeptid. Download PDF

Info

Publication number: NO326523B1
Authority: NO; Norway
Prior art keywords: polypeptide; cell; cells; antibody; stated
Prior art date: 1998-04-21

Application number

NO20005296A

Other languages

English (en)

Norwegian (no)

Other versions

NO20005296L (no

NO20005296D0 (no

Inventor

Peter Kufer

Bernd Dorken

Gert Riethmueller

Ralf Lutterbuese

Ralf Bargou

Anja Loffler

Original Assignee

Micromet Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-21

Filing date

2000-10-20

Publication date

2008-12-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8231795&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO326523(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-10-20 Application filed by Micromet Ag filed Critical Micromet Ag

2000-10-20 Publication of NO20005296D0 publication Critical patent/NO20005296D0/no

2000-12-13 Publication of NO20005296L publication Critical patent/NO20005296L/no

2008-12-22 Publication of NO326523B1 publication Critical patent/NO326523B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 178
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 163
229920001184 polypeptide Polymers 0.000 title claims abstract description 160
102000040430 polynucleotide Human genes 0.000 title claims abstract description 53
108091033319 polynucleotide Proteins 0.000 title claims abstract description 53
239000002157 polynucleotide Substances 0.000 title claims abstract description 53
239000013598 vector Substances 0.000 title claims abstract description 48
238000002360 preparation method Methods 0.000 title claims abstract description 15
239000000203 mixture Substances 0.000 title claims abstract description 10
238000000034 method Methods 0.000 title claims description 75
210000004027 cell Anatomy 0.000 claims abstract description 120
230000027455 binding Effects 0.000 claims abstract description 60
210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 56
239000000427 antigen Substances 0.000 claims abstract description 40
102000036639 antigens Human genes 0.000 claims abstract description 40
108091007433 antigens Proteins 0.000 claims abstract description 40
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims abstract description 31
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims abstract description 31
206010028980 Neoplasm Diseases 0.000 claims abstract description 30
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims abstract description 28
238000004519 manufacturing process Methods 0.000 claims abstract description 16
230000036210 malignancy Effects 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract 4
210000001744 T-lymphocyte Anatomy 0.000 claims description 46
150000001875 compounds Chemical class 0.000 claims description 41
238000011282 treatment Methods 0.000 claims description 38
150000001413 amino acids Chemical group 0.000 claims description 34
201000011510 cancer Diseases 0.000 claims description 19
230000014509 gene expression Effects 0.000 claims description 19
230000001404 mediated effect Effects 0.000 claims description 18
239000002773 nucleotide Substances 0.000 claims description 15
125000003729 nucleotide group Chemical group 0.000 claims description 15
108060003951 Immunoglobulin Proteins 0.000 claims description 14
239000012634 fragment Substances 0.000 claims description 14
102000018358 immunoglobulin Human genes 0.000 claims description 14
239000000825 pharmaceutical preparation Substances 0.000 claims description 13
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 12
230000006044 T cell activation Effects 0.000 claims description 12
239000012636 effector Substances 0.000 claims description 12
230000004044 response Effects 0.000 claims description 12
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 11
208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 11
108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
239000003112 inhibitor Substances 0.000 claims description 8
238000001514 detection method Methods 0.000 claims description 7
230000003993 interaction Effects 0.000 claims description 7
208000003950 B-cell lymphoma Diseases 0.000 claims description 6
238000001415 gene therapy Methods 0.000 claims description 6
208000023275 Autoimmune disease Diseases 0.000 claims description 5
230000004071 biological effect Effects 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
230000000638 stimulation Effects 0.000 claims description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
239000012190 activator Substances 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
208000037914 B-cell disorder Diseases 0.000 claims description 3
230000004913 activation Effects 0.000 claims description 3
150000002500 ions Chemical class 0.000 claims description 3
HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 claims description 2
239000004471 Glycine Substances 0.000 claims description 2
208000024869 Goodpasture syndrome Diseases 0.000 claims description 2
208000001204 Hashimoto Disease Diseases 0.000 claims description 2
208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
235000004279 alanine Nutrition 0.000 claims description 2
125000000539 amino acid group Chemical group 0.000 claims description 2
238000012258 culturing Methods 0.000 claims description 2
206010028417 myasthenia gravis Diseases 0.000 claims description 2
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
230000000536 complexating effect Effects 0.000 claims 1
230000001575 pathological effect Effects 0.000 claims 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract description 13
238000009169 immunotherapy Methods 0.000 abstract description 7
108090000623 proteins and genes Proteins 0.000 description 42
239000003814 drug Substances 0.000 description 30
229940079593 drug Drugs 0.000 description 27
102000004169 proteins and genes Human genes 0.000 description 25
235000018102 proteins Nutrition 0.000 description 23
230000001472 cytotoxic effect Effects 0.000 description 20
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
230000003013 cytotoxicity Effects 0.000 description 18
231100000135 cytotoxicity Toxicity 0.000 description 18
108020004414 DNA Proteins 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
201000010099 disease Diseases 0.000 description 15
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
108010047041 Complementarity Determining Regions Proteins 0.000 description 14
239000000126 substance Substances 0.000 description 14
206010025323 Lymphomas Diseases 0.000 description 12
235000001014 amino acid Nutrition 0.000 description 12
230000003211 malignant effect Effects 0.000 description 12
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
210000000952 spleen Anatomy 0.000 description 12
239000000872 buffer Substances 0.000 description 11
238000000746 purification Methods 0.000 description 11
230000001225 therapeutic effect Effects 0.000 description 11
238000007792 addition Methods 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
102000004127 Cytokines Human genes 0.000 description 9
108090000695 Cytokines Proteins 0.000 description 9
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
230000000139 costimulatory effect Effects 0.000 description 9
230000000694 effects Effects 0.000 description 9
238000011534 incubation Methods 0.000 description 9
108010074051 C-Reactive Protein Proteins 0.000 description 8
102100032752 C-reactive protein Human genes 0.000 description 8
241000276498 Pollachius virens Species 0.000 description 8
230000036765 blood level Effects 0.000 description 8
239000011651 chromium Substances 0.000 description 8
239000013604 expression vector Substances 0.000 description 8
108020004206 Gamma-glutamyltransferase Proteins 0.000 description 7
102000000588 Interleukin-2 Human genes 0.000 description 7
108010002350 Interleukin-2 Proteins 0.000 description 7
210000004899 c-terminal region Anatomy 0.000 description 7
230000009089 cytolysis Effects 0.000 description 7
238000001647 drug administration Methods 0.000 description 7
102000006640 gamma-Glutamyltransferase Human genes 0.000 description 7
210000000265 leukocyte Anatomy 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000003556 assay Methods 0.000 description 6
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 6
210000004408 hybridoma Anatomy 0.000 description 6
238000001802 infusion Methods 0.000 description 6
210000001165 lymph node Anatomy 0.000 description 6
239000002609 medium Substances 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
150000007523 nucleic acids Chemical class 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
102000005962 receptors Human genes 0.000 description 6
108020003175 receptors Proteins 0.000 description 6
239000003053 toxin Substances 0.000 description 6
231100000765 toxin Toxicity 0.000 description 6
108700012359 toxins Proteins 0.000 description 6
238000002604 ultrasonography Methods 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
102000004889 Interleukin-6 Human genes 0.000 description 5
108090001005 Interleukin-6 Proteins 0.000 description 5
102000004890 Interleukin-8 Human genes 0.000 description 5
108090001007 Interleukin-8 Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
241000700605 Viruses Species 0.000 description 5
230000009471 action Effects 0.000 description 5
238000001042 affinity chromatography Methods 0.000 description 5
238000005277 cation exchange chromatography Methods 0.000 description 5
238000004113 cell culture Methods 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
231100000433 cytotoxic Toxicity 0.000 description 5
238000011161 development Methods 0.000 description 5
230000018109 developmental process Effects 0.000 description 5
238000010828 elution Methods 0.000 description 5
238000000684 flow cytometry Methods 0.000 description 5
230000006870 function Effects 0.000 description 5
230000004927 fusion Effects 0.000 description 5
238000002523 gelfiltration Methods 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
230000001900 immune effect Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
229940100601 interleukin-6 Drugs 0.000 description 5
229940096397 interleukin-8 Drugs 0.000 description 5
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
230000003278 mimic effect Effects 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
-1 radioisotopes Substances 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
102000010789 Interleukin-2 Receptors Human genes 0.000 description 4
108010038453 Interleukin-2 Receptors Proteins 0.000 description 4
208000007452 Plasmacytoma Diseases 0.000 description 4
239000012980 RPMI-1640 medium Substances 0.000 description 4
108091008874 T cell receptors Proteins 0.000 description 4
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
229910052804 chromium Inorganic materials 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
239000003550 marker Substances 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
239000013642 negative control Substances 0.000 description 4
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000012546 transfer Methods 0.000 description 4
241000196324 Embryophyta Species 0.000 description 3
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
102000008100 Human Serum Albumin Human genes 0.000 description 3
108091006905 Human Serum Albumin Proteins 0.000 description 3
102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 description 3
108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 description 3
102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
206010041660 Splenomegaly Diseases 0.000 description 3
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
230000000340 anti-metabolite Effects 0.000 description 3
239000002256 antimetabolite Substances 0.000 description 3
229940100197 antimetabolite Drugs 0.000 description 3
230000000975 bioactive effect Effects 0.000 description 3
229910002091 carbon monoxide Inorganic materials 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
229960004630 chlorambucil Drugs 0.000 description 3
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 3
PMGQWSIVQFOFOQ-YKVZVUFRSA-N clemastine fumarate Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-YKVZVUFRSA-N 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
239000003446 ligand Substances 0.000 description 3
239000002502 liposome Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
244000005700 microbiome Species 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
229960004618 prednisone Drugs 0.000 description 3
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
230000006641 stabilisation Effects 0.000 description 3
238000011105 stabilization Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000002636 symptomatic treatment Methods 0.000 description 3
229940106721 tagamet Drugs 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
230000014616 translation Effects 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
241000702421 Dependoparvovirus Species 0.000 description 2
102100024746 Dihydrofolate reductase Human genes 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
108090001090 Lectins Proteins 0.000 description 2
102000004856 Lectins Human genes 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
102000052812 Ornithine decarboxylases Human genes 0.000 description 2
108700005126 Ornithine decarboxylases Proteins 0.000 description 2
KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
108010039491 Ricin Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
229940126530 T cell activator Drugs 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000003321 amplification Effects 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
238000010171 animal model Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
YTCZZXIRLARSET-VJRSQJMHSA-M beraprost sodium Chemical compound [Na+].O([C@H]1C[C@@H](O)[C@@H]([C@@H]21)/C=C/[C@@H](O)C(C)CC#CC)C1=C2C=CC=C1CCCC([O-])=O YTCZZXIRLARSET-VJRSQJMHSA-M 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
238000002306 biochemical method Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000001772 blood platelet Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000009084 cardiovascular function Effects 0.000 description 2
238000005341 cation exchange Methods 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
108020001096 dihydrofolate reductase Proteins 0.000 description 2
239000000539 dimer Substances 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000002523 lectin Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
210000003519 mature b lymphocyte Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229930192851 perforin Natural products 0.000 description 2
210000004976 peripheral blood cell Anatomy 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
IHEHEFLXQFOQJO-UHFFFAOYSA-N piritramide Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 IHEHEFLXQFOQJO-UHFFFAOYSA-N 0.000 description 2
229960001286 piritramide Drugs 0.000 description 2
FKKAEMQFOIDZNY-CODXZCKSSA-M prednisolone sodium succinate Chemical compound [Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COC(=O)CCC([O-])=O)[C@@H]4[C@@H]3CCC2=C1 FKKAEMQFOIDZNY-CODXZCKSSA-M 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
229960004641 rituximab Drugs 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
241000894007 species Species 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
206010043554 thrombocytopenia Diseases 0.000 description 2
238000013519 translation Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
206010048998 Acute phase reaction Diseases 0.000 description 1
102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102100036826 Aldehyde oxidase Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102100029727 Enteropeptidase Human genes 0.000 description 1
108010013369 Enteropeptidase Proteins 0.000 description 1
244000258539 Epigaea repens Species 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
241000736355 Euthyroides Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
206010018498 Goitre Diseases 0.000 description 1
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
108010093488 His-His-His-His-His-His Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
201000001431 Hyperuricemia Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010027603 Migraine headaches Diseases 0.000 description 1
101100366881 Mus musculus Stat3 gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
108010077850 Nuclear Localization Signals Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229940122060 Ornithine decarboxylase inhibitor Drugs 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000220317 Rosa Species 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
241000607715 Serratia marcescens Species 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
108010088160 Staphylococcal Protein A Proteins 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000013566 allergen Substances 0.000 description 1
OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
229960003459 allopurinol Drugs 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000003388 anti-hormonal effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
235000021028 berry Nutrition 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000010170 biological method Methods 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 description 1
229960001704 carbimazole Drugs 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
238000012219 cassette mutagenesis Methods 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
230000004715 cellular signal transduction Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
229960002881 clemastine Drugs 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000012568 clinical material Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000002967 competitive immunoassay Methods 0.000 description 1
238000004590 computer program Methods 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000294 dose-dependent toxicity Toxicity 0.000 description 1
231100000371 dose-limiting toxicity Toxicity 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
239000000284 extract Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
210000002980 germ line cell Anatomy 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
108060003196 globin Proteins 0.000 description 1
102000018146 globin Human genes 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
108091005608 glycosylated proteins Proteins 0.000 description 1
102000035122 glycosylated proteins Human genes 0.000 description 1
201000003872 goiter Diseases 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
208000029824 high grade glioma Diseases 0.000 description 1
101150113423 hisD gene Proteins 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
208000000122 hyperventilation Diseases 0.000 description 1
230000000870 hyperventilation Effects 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
230000000998 lymphohematopoietic effect Effects 0.000 description 1
210000005210 lymphoid organ Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
201000011614 malignant glioma Diseases 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
231100001083 no cytotoxicity Toxicity 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229960000381 omeprazole Drugs 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000002818 ornithine decarboxylase inhibitor Substances 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
229960000482 pethidine Drugs 0.000 description 1
238000002823 phage display Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
230000007096 poisonous effect Effects 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
229950010131 puromycin Drugs 0.000 description 1
108010045647 puromycin N-acetyltransferase Proteins 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000035900 sweating Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
101150081616 trpB gene Proteins 0.000 description 1
101150111232 trpB-1 gene Proteins 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Cell Biology (AREA)
General Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

NO20005296A 1998-04-21 2000-10-20 CD19xCD3-spesifikke polypeptid, vektor, celle, sammensetning, fremgangsmate for fremstilling samt anvendelse av nevnte polypeptid eller et polynukleotid som koder for nevnte polypeptid. NO326523B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98107269		1998-04-21
PCT/EP1999/002693 WO1999054440A1 (en)	1998-04-21	1999-04-21	CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF

Publications (3)

Publication Number	Publication Date
NO20005296D0 NO20005296D0 (no)	2000-10-20
NO20005296L NO20005296L (no)	2000-12-13
NO326523B1 true NO326523B1 (no)	2008-12-22

Family

ID=8231795

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20005296A NO326523B1 (no)	1998-04-21	2000-10-20	CD19xCD3-spesifikke polypeptid, vektor, celle, sammensetning, fremgangsmate for fremstilling samt anvendelse av nevnte polypeptid eller et polynukleotid som koder for nevnte polypeptid.

Country Status (29)

Country	Link
US (2)	US7112324B1 (pt)
EP (2)	EP1348715A3 (pt)
JP (1)	JP4169478B2 (pt)
KR (1)	KR100508289B1 (pt)
CN (1)	CN1302103C (pt)
AT (1)	ATE244758T1 (pt)
AU (1)	AU761587B2 (pt)
BR (1)	BRPI9909860B8 (pt)
CA (1)	CA2326389C (pt)
CU (1)	CU23252B7 (pt)
CZ (1)	CZ302070B6 (pt)
DE (1)	DE69909459T2 (pt)
DK (1)	DK1071752T3 (pt)
ES (1)	ES2203141T3 (pt)
HK (1)	HK1037674A1 (pt)
HR (1)	HRP20000714B1 (pt)
HU (1)	HU229039B1 (pt)
ID (1)	ID27512A (pt)
IL (2)	IL138857A0 (pt)
NO (1)	NO326523B1 (pt)
NZ (1)	NZ507381A (pt)
PL (1)	PL199747B1 (pt)
PT (1)	PT1071752E (pt)
RU (1)	RU2228202C2 (pt)
SI (1)	SI1071752T1 (pt)
SK (1)	SK286683B6 (pt)
TR (1)	TR200003087T2 (pt)
WO (1)	WO1999054440A1 (pt)
ZA (1)	ZA200005866B (pt)

Families Citing this family (406)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999054440A1 (en) *	1998-04-21	1999-10-28	Micromet Gesellschaft Für Biomedizinische Forschung Mbh	CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
MXPA01011279A (es)	1999-05-07	2002-07-02	Genentech Inc	Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
US8119101B2 (en)	1999-05-10	2012-02-21	The Ohio State University	Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en)	1999-05-10	2010-11-09	Immunomedics, Inc.	Anti-CD74 immunoconjugates and methods
US8383081B2 (en)	1999-05-10	2013-02-26	Immunomedics, Inc.	Anti-CD74 immunoconjugates and methods of use
EP1543839B1 (en) *	1999-06-09	2017-09-20	Immunomedics, Inc.	Immunotherapy of autoimmune disorders using antibodies which target B-cells
AU782160B2 (en)	1999-06-09	2005-07-07	Immunomedics Inc.	Immunotherapy of autoimmune disorders using antibodies which target B-cells
DE19962583A1 (de) *	1999-12-23	2001-06-28	Mueller Hermelink Hans Konrad	Antikörper gegen Plasmazellen
AU2001297703B2 (en)	2000-11-07	2006-10-19	City Of Hope	CD19-specific redirected immune cells
US20080260731A1 (en) *	2002-03-01	2008-10-23	Bernett Matthew J	Optimized antibodies that target cd19
US9770517B2 (en)	2002-03-01	2017-09-26	Immunomedics, Inc.	Anti-Trop-2 antibody-drug conjugates and uses thereof
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US9453251B2 (en)	2002-10-08	2016-09-27	Pfenex Inc.	Expression of mammalian proteins in Pseudomonas fluorescens
US7820166B2 (en)	2002-10-11	2010-10-26	Micromet Ag	Potent T cell modulating molecules
EP1629012B1 (en) *	2003-05-31	2018-11-28	Amgen Research (Munich) GmbH	Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
ATE455127T1 (de)	2003-05-31	2010-01-15	Micromet Ag	Humane anti-humane cd3-bindungsmoleküle
CA2528549A1 (en)	2003-06-06	2005-06-02	Medimmune, Inc.	Use of epha4 and modulator of epha4 for diagnosis, treatment and prevention of cancer
JP4733635B2 (ja) *	2003-07-31	2011-07-27	イミューノメディクス、インコーポレイテッド	抗ｃｄ１９抗体
US7902338B2 (en)	2003-07-31	2011-03-08	Immunomedics, Inc.	Anti-CD19 antibodies
KR20120125634A (ko)	2003-10-16	2012-11-16	마이크로메트 에이지	다중특이적 탈면역화된 ｃｄ3-바인더
US10000574B2 (en) *	2003-11-28	2018-06-19	Amgen Research (Munich) Gmbh	Compositions comprising polypeptides
US7235641B2 (en) *	2003-12-22	2007-06-26	Micromet Ag	Bispecific antibodies
US8883160B2 (en)	2004-02-13	2014-11-11	Ibc Pharmaceuticals, Inc.	Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en)	2004-02-13	2017-01-24	Ibc Pharmaceuticals, Inc.	Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
ATE477277T1 (de) *	2004-02-16	2010-08-15	Micromet Ag	Weniger immunogene bindungsmoleküle
WO2006014899A2 (en)	2004-07-26	2006-02-09	Dow Global Technologies Inc.	Process for improved protein expression by strain engineering
EP2422811A2 (en)	2004-10-27	2012-02-29	MedImmune, LLC	Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en)	2015-06-25	2018-08-28	Immunomedics, Inc.	Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en)	2013-07-23	2017-07-18	Immunomedics, Inc.	Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US8475794B2 (en)	2005-04-06	2013-07-02	Ibc Pharmaceuticals, Inc.	Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en)	2005-04-06	2013-01-08	Ibc Pharmaceuticals, Inc.	Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
ES2545769T3 (es)	2005-04-18	2015-09-15	Amgen Research (Munich) Gmbh	Anticuerpos neutralizantes del factor estimulante de colonias de granulocitos y macrófagos humano
JP5129122B2 (ja)	2005-04-26	2013-01-23	トリオンファーマゲーエムベーハー	癌治療のための抗体およびグルココルチコイドの組み合わせ
WO2007002223A2 (en) *	2005-06-20	2007-01-04	Medarex, Inc.	Cd19 antibodies and their uses
EP1928506A4 (en) *	2005-08-19	2009-10-21	Abbott Lab	IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF
JP5686953B2 (ja) *	2005-10-11	2015-03-18	アムゲンリサーチ（ミュンヘン）ゲーエムベーハー	交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
CA2633594C (en) *	2005-12-16	2021-10-26	Micromet Ag	Means and methods for the treatment of tumorous diseases
NZ569204A (en)	2005-12-21	2012-03-30	Micromet Ag	Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA
EP1989544B1 (en) *	2006-03-02	2011-06-22	Antitope Limited	T cell assays
WO2008022152A2 (en) *	2006-08-14	2008-02-21	Xencor, Inc.	Optimized antibodies that target cd19
ATE551071T1 (de) *	2006-09-08	2012-04-15	Medimmune Llc	Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
WO2008119566A2 (en) *	2007-04-03	2008-10-09	Micromet Ag	Cross-species-specific bispecific binders
BRPI0809594A2 (pt) *	2007-04-03	2019-08-27	Micromet Ag	polipeptídeo, seqüência de ácido nucléico, vetor, hospedeiro, processo para a produção de um polipeptídeo, composição farmacêutica, uso de um polipeptídeo, método para prevenção, tratamento ou melhora de uma doença, em um indivíduo com necessidade do mesmo, kit, método para a identificação de um polipeptídeo(s)
NZ580755A (en)	2007-04-03	2012-05-25	Micromet Ag	Cross-species-specific cd3-epsilon binding domain
US9580719B2 (en)	2007-04-27	2017-02-28	Pfenex, Inc.	Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
AU2008245696B2 (en)	2007-04-27	2013-11-07	Pelican Technology Holdings, Inc.	Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
KR101643514B1 (ko)	2007-07-09	2016-07-27	제넨테크, 인크.	폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CN101952415B (zh) *	2007-07-31	2017-06-27	生命扫描有限公司	人胚胎干细胞的分化
JP2010535032A (ja)	2007-07-31	2010-11-18	メディミューン，エルエルシー	多重特異性エピトープ結合性タンパク質およびその用途
JP5727786B2 (ja) *	2007-10-19	2015-06-03	シアトルジェネティクス，インコーポレーテッド	Ｃｄ１９結合性物質およびその使用
US9308257B2 (en)	2007-11-28	2016-04-12	Medimmune, Llc	Protein formulation
CN102164961B (zh) *	2008-10-01	2014-04-16	安进研发（慕尼黑）股份有限公司	种间特异性PSCAxCD3、CD19xCD3、C-METxCD3、内皮唾液酸蛋白xCD3、EpCAMxCD3、IGF-1RxCD3或FAPαxCD3双特异性单链抗体
EP2352765B1 (en)	2008-10-01	2018-01-03	Amgen Research (Munich) GmbH	Cross-species-specific single domain bispecific single chain antibody
SI2356153T1 (sl)	2008-10-01	2016-07-29	Amgen Research (Munich) Gmbh	Bispecifično enoverižno protitelo, specifično za križane vrste
SI2352763T2 (sl)	2008-10-01	2022-11-30	Amgen Research (Munich) Gmbh	Bispecifična enoverižna protitelesa s specifičnostjo za tarčne antigene z visoko molekulsko maso
KR101695329B1 (ko)	2008-11-07	2017-01-23	암젠 리서치 (뮌헨) 게엠베하	소아 급성 림프구성 백혈병의 치료방법
LT2982696T (lt)	2008-11-07	2019-06-10	Amgen Research (Munich) Gmbh	Ūmios limfoblastinės leukemijos gydymas
US8993808B2 (en)	2009-01-21	2015-03-31	Oryzon Genomics, S.A.	Phenylcyclopropylamine derivatives and their medical use
US9676845B2 (en) *	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
CN102597005A (zh)	2009-06-23	2012-07-18	阿雷克森制药公司	与补体蛋白质结合的双特异性抗体
WO2011028952A1 (en)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
MX338041B (es)	2009-09-25	2016-03-30	Oryzon Genomics Sa	Inhibidores de demetilasa-1 especificos de lisina y su uso.
US8946296B2 (en)	2009-10-09	2015-02-03	Oryzon Genomics S.A.	Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
ME02947B (me) *	2009-10-27	2018-04-20	Amgen Res Munich Gmbh	Režim doziranja kod primjene dvojno specifičnog protutijela cd19xcd3
KR20120123299A (ko)	2009-12-04	2012-11-08	제넨테크, 인크.	다중특이적 항체, 항체 유사체, 조성물 및 방법
WO2011079283A1 (en) *	2009-12-23	2011-06-30	Bioalliance C.V.	Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
WO2011106574A2 (en)	2010-02-24	2011-09-01	Oryzon Genomics, S.A.	Inhibitors for antiviral use
US9186337B2 (en)	2010-02-24	2015-11-17	Oryzon Genomics S.A.	Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
TWI653333B (zh)	2010-04-01	2019-03-11	安進研究（慕尼黑）有限責任公司	跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
ES2607081T3 (es)	2010-04-19	2017-03-29	Oryzon Genomics, S.A.	Inhibidores de desmetilasa específica de lisina-1 y su uso
BR112012028010A2 (pt)	2010-05-03	2017-09-26	Genentech Inc	anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
CN102985410B (zh)	2010-05-05	2015-05-27	拜罗伊特大学	在癌症的治疗中使用的考布他汀类似物
CN102250245B (zh) *	2010-05-27	2014-05-14	四川大学	抗b细胞淋巴瘤的双特异性抗体及其用途
EP2598512A1 (en)	2010-07-28	2013-06-05	Medizinische Universität Wien	Vinylogous chalcone derivatives and their medical use
EP2598480B1 (en)	2010-07-29	2019-04-24	Oryzon Genomics, S.A.	Cyclopropylamine derivatives useful as lsd1 inhibitors
AU2011283694B2 (en)	2010-07-29	2017-04-13	Xencor, Inc.	Antibodies with modified isoelectric points
LT2598482T (lt)	2010-07-29	2018-07-10	Oryzon Genomics, S.A.	Demetilazės lsd1 inhibitoriai arilciklopropilamino pagrindu ir jų medicininis panaudojimas
WO2012045883A1 (en)	2010-10-08	2012-04-12	Oryzon Genomics S.A.	Cyclopropylamine inhibitors of oxidases
SG189869A1 (en)	2010-10-27	2013-06-28	Amgen Res Munich Gmbh	Means and methods for treating dlbcl
CA2816668C (en)	2010-11-10	2021-03-23	Amgen Research (Munich) Gmbh	Prevention of adverse effects caused by cd3 specific binding domains
US20130273055A1 (en) *	2010-11-16	2013-10-17	Eric Borges	Agents and methods for treating diseases that correlate with bcma expression
WO2012072713A2 (en)	2010-11-30	2012-06-07	Oryzon Genomics, S.A.	Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
WO2012107498A1 (en)	2011-02-08	2012-08-16	Oryzon Genomics S.A.	Lysine demethylase inhibitors for myeloproliferative disorders
WO2012109624A2 (en)	2011-02-11	2012-08-16	Zyngenia, Inc.	Monovalent and multivalent multispecific complexes and uses thereof
KR102147533B1 (ko)	2011-04-28	2020-08-25	암젠 리서치 (뮌헨) 게엠베하	잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법
EP2714733B1 (en)	2011-05-21	2019-01-23	MacroGenics, Inc.	Cd3-binding molecules capable of binding to human and non-human cd3
WO2012162561A2 (en)	2011-05-24	2012-11-29	Zyngenia, Inc.	Multivalent and monovalent multispecific complexes and their uses
EP3385280A1 (en)	2011-06-10	2018-10-10	MedImmune Limited	Anti-pseudomonas psl binding molecules and uses thereof
ES2909722T3 (es) *	2011-08-16	2022-05-10	Morphosys Ag	Terapia de combinación con un anticuerpo anti-CD19 y una mostaza nitrogenada
DE202012012998U1 (de)	2011-08-31	2014-06-13	Daniel Elias	Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
CA2846432A1 (en)	2011-09-23	2013-03-28	Amgen Research (Munich) Gmbh	Bispecific binding molecules for 5t4 and cd3
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
BR112014009306B1 (pt)	2011-10-20	2021-07-20	Oryzon Genomics S.A.	Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1
CA2849564C (en)	2011-10-20	2020-10-20	Oryzon Genomics, S.A.	(hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
RS60920B1 (sr)	2011-11-07	2020-11-30	Medimmune Ltd	Kombinovane terapije primenom anti-pseudomonas psl i pcrv vezujućih molekula
TWI679212B (zh)	2011-11-15	2019-12-11	美商安進股份有限公司	針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9757458B2 (en)	2011-12-05	2017-09-12	Immunomedics, Inc.	Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
EP2788020A4 (en)	2011-12-05	2015-04-29	Immunomedics Inc	THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS
US10633451B2 (en) *	2012-02-03	2020-04-28	Hoffmann-La Roche Inc.	Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
WO2013126712A1 (en)	2012-02-22	2013-08-29	The Trustees Of The University Of Pennsylvania	Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
GB201203442D0 (en)	2012-02-28	2012-04-11	Univ Birmingham	Immunotherapeutic molecules and uses
MX353382B (es)	2012-03-01	2018-01-10	Amgen Res Munich Gmbh	Moleculas de union polipeptido de larga duracion.
CN103382223B (zh)	2012-04-01	2015-06-10	上海益杰生物技术有限公司	针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
WO2014004549A2 (en)	2012-06-27	2014-01-03	Amgen Inc.	Anti-mesothelin binding proteins
BR112015000638A2 (pt)	2012-07-13	2017-08-08	Univ Pennsylvania	sequência de ácido nucleico isolada, célula, métodos para estimular uma resposta imune mediada pela célula t e uma população de célula alvo ou tecido em um mamífero, para provimento de imunidade antitumor em um mamífero, para tratamento de um mamífero que tenha uma doença, distúrbio ou condição associado com uma expressão elevada de um antígeno de tumor
US9382329B2 (en)	2012-08-14	2016-07-05	Ibc Pharmaceuticals, Inc.	Disease therapy by inducing immune response to Trop-2 expressing cells
US9682143B2 (en)	2012-08-14	2017-06-20	Ibc Pharmaceuticals, Inc.	Combination therapy for inducing immune response to disease
US20150231241A1 (en)	2012-08-14	2015-08-20	Ibc Pharmaceuticals, Inc.	Combination therapy for inducing immune response to disease
AU2013302696B9 (en)	2012-08-14	2018-08-09	Ibc Pharmaceuticals, Inc.	T-cell redirecting bispecific antibodies for treatment of disease
US10131712B2 (en)	2012-08-14	2018-11-20	Ibc Pharmaceuticals, Inc.	Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
JOP20200236A1 (ar)	2012-09-21	2017-06-16	Regeneron Pharma	الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
AR093297A1 (es)	2012-10-31	2015-05-27	Amgen Res (Munich) Gmbh	Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en)	2012-10-31	2019-05-22	Takeda GmbH	Lyophilized formulation comprising gm-csf neutralizing compound
CN103833852A (zh) *	2012-11-23	2014-06-04	上海市肿瘤研究所	针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
US9492566B2 (en)	2012-12-13	2016-11-15	Immunomedics, Inc.	Antibody-drug conjugates and uses thereof
US10206918B2 (en)	2012-12-13	2019-02-19	Immunomedics, Inc.	Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10137196B2 (en)	2012-12-13	2018-11-27	Immunomedics, Inc.	Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
BR112015013444B1 (pt)	2012-12-13	2022-11-01	Immunomedics, Inc	Uso de um imunoconjugado
US9931417B2 (en)	2012-12-13	2018-04-03	Immunomedics, Inc.	Antibody-SN-38 immunoconjugates with a CL2A linker
US10413539B2 (en)	2012-12-13	2019-09-17	Immunomedics, Inc.	Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10744129B2 (en)	2012-12-13	2020-08-18	Immunomedics, Inc.	Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9107960B2 (en)	2012-12-13	2015-08-18	Immunimedics, Inc.	Antibody-SN-38 immunoconjugates with a CL2A linker
EP3620473A1 (en)	2013-01-14	2020-03-11	Xencor, Inc.	Novel heterodimeric proteins
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
EP2945969A1 (en)	2013-01-15	2015-11-25	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
CN103965359B (zh) *	2013-01-24	2016-08-03	上海市肿瘤研究所	抗上皮细胞粘附分子和t细胞抗原的双特异性抗体
JO3519B1 (ar)	2013-01-25	2020-07-05	Amgen Inc	تركيبات أجسام مضادة لأجل cdh19 و cd3
US9920121B2 (en)	2013-01-25	2018-03-20	Amgen Inc.	Antibodies targeting CDH19 for melanoma
JO3529B1 (ar)	2013-02-08	2020-07-05	Amgen Res Munich Gmbh	مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
US9486475B2 (en)	2013-02-08	2016-11-08	Amgen Research (Munich) Gmbh	PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
US20160000842A1 (en)	2013-03-05	2016-01-07	Baylor College Of Medicine	Oncolytic virus
WO2014138306A1 (en)	2013-03-05	2014-09-12	Baylor College Of Medicine	Engager cells for immunotherapy
AR095596A1 (es)	2013-03-15	2015-10-28	Amgen Res (Munich) Gmbh	Moléculas de unión de cadena única comprendiendo n-terminal abp
US9802995B2 (en) *	2013-03-15	2017-10-31	Memorial Sloan-Kettering Cancer Center	Antibody multimerization technologies
US20140302037A1 (en) *	2013-03-15	2014-10-09	Amgen Inc.	BISPECIFIC-Fc MOLECULES
US9561291B2 (en) *	2013-03-15	2017-02-07	Imre Kovesdi	Methods of targeting T-cells to tumors
US10150800B2 (en)	2013-03-15	2018-12-11	Zyngenia, Inc.	EGFR-binding modular recognition domains
US9505849B2 (en)	2013-03-15	2016-11-29	Amgen Research (Munich) Gmbh	Antibody constructs for influenza M2 and CD3
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
AR095374A1 (es)	2013-03-15	2015-10-14	Amgen Res (Munich) Gmbh	Moléculas de unión para bcma y cd3
EP3421495A3 (en)	2013-03-15	2019-05-15	Xencor, Inc.	Modulation of t cells with bispecific antibodies and fc fusions
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
CN107460201A (zh) *	2013-05-08	2017-12-12	科济生物医药（上海）有限公司	编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
KR20160007604A (ko)	2013-05-10	2016-01-20	누맙 아게	이중특이성 작제물 및 다양한 질병의 치료에서의 이의 용도
WO2015006482A1 (en) *	2013-07-09	2015-01-15	Duke University	CERTAIN IMPROVED HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
US11253606B2 (en)	2013-07-23	2022-02-22	Immunomedics, Inc.	Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN104342453A (zh) *	2013-08-06	2015-02-11	深圳先进技术研究院	含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
MX2016002177A (es)	2013-08-30	2016-06-28	Takeda Gmbh	Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
TWI688401B (zh)	2013-09-13	2020-03-21	美商安進公司	用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
JP6502931B2 (ja)	2013-10-11	2019-04-17	アメリカ合衆国	Ｔｅｍ８抗体およびその使用
CN104623637A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	Il-22二聚体在制备静脉注射药物中的应用
WO2015103549A1 (en)	2014-01-03	2015-07-09	The United States Of America, As Represented By The Secretary Department Of Health And Human Services	Neutralizing antibodies to hiv-1 env and their use
AU2015219495B2 (en)	2014-02-21	2019-11-21	Ibc Pharmaceuticals, Inc.	Disease therapy by inducing immune response to Trop-2 expressing cells
EP3110445A4 (en)	2014-02-25	2017-09-27	Immunomedics, Inc.	Humanized rfb4 anti-cd22 antibody
TWI754319B (zh)	2014-03-19	2022-02-01	美商再生元醫藥公司	用於腫瘤治療之方法及抗體組成物
UA119167C2 (uk)	2014-03-28	2019-05-10	Зенкор, Інк.	Біспецифічне антитіло, яке зв'язується з cd38 та cd3
RU2577226C2 (ru) *	2014-04-10	2016-03-10	Общество с ограниченной ответственностью, "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум")	Способ получения биспецифических антител против cd3*cd19 формата флексибоди в клетках млекопитающих
RU2568910C2 (ru) *	2014-04-18	2015-11-20	Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум")	Фармацевтические композиции на основе флексибоди против cd3*cd19 для лечения в-клеточных заболеваний
CN105017422A (zh) *	2014-04-30	2015-11-04	山东百因制药技术有限公司	一种抗cd3/抗cd19双特异性抗体及其应用
BR112016025126B1 (pt)	2014-05-07	2024-02-15	Takeda Pharmaceutical Company Limited	Composição aquosa compreendendo anticorpo neutralizante de gmcsf, e uso da mesma
WO2015172341A1 (zh) *	2014-05-14	2015-11-19	上海市肿瘤研究所	针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
EP2947460A1 (en)	2014-05-22	2015-11-25	Medizinische Universität Wien	Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
PL3531133T3 (pl)	2014-05-30	2024-01-29	Amgen Research (Munich) Gmbh	Stratyfikacja ryzyka u pacjentów z ostrą białaczką limfoblastyczną z prekursorów b
MX2016017393A (es)	2014-07-01	2017-09-05	Pfizer	Diacuerpos heterodimericos biespecificos y sus usos.
EP3172235A2 (en)	2014-07-25	2017-05-31	Cytomx Therapeutics Inc.	Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
AU2015294834B2 (en)	2014-07-31	2021-04-29	Amgen Research (Munich) Gmbh	Optimized cross-species specific bispecific single chain antibody constructs
AR101669A1 (es)	2014-07-31	2017-01-04	Amgen Res (Munich) Gmbh	Constructos de anticuerpos para cdh19 y cd3
MX2017001403A (es)	2014-07-31	2017-07-07	Amgen Res (Munich) Gmbh	Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
EP3186237A1 (en)	2014-08-28	2017-07-05	Medizinische Universität Wien	Heteroaromatic chalcone derivatives and their medical use
WO2016077789A1 (en)	2014-11-14	2016-05-19	The Usa, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to ebola virus glycoprotein and their use
HUE050831T2 (hu)	2014-11-17	2021-01-28	Regeneron Pharma	Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával
EP3223845B1 (en)	2014-11-26	2021-05-19	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cd20
CN107406512A (zh)	2014-11-26	2017-11-28	Xencor公司	结合cd3和cd38的异二聚体抗体
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
EP3029067A1 (en)	2014-12-01	2016-06-08	Deutsches Krebsforschungszentrum	Use of blocking-reagents for reducing unspecific T cell-activation
US20160168237A1 (en)	2014-12-12	2016-06-16	Alexion Pharmaceuticals, Inc.	Method for treating a complement mediated disorder caused by an infectious agent in a patient
WO2016105450A2 (en)	2014-12-22	2016-06-30	Xencor, Inc.	Trispecific antibodies
PE20171764A1 (es)	2015-01-23	2017-12-21	Sanofi Sa	Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
WO2016135140A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
RU2722832C2 (ru)	2015-02-23	2020-06-04	Сигалл Терапьютикс Сас	Неприродные семафорины класса 3 и их медицинское применение
WO2016135137A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en)	2015-02-23	2016-09-01	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
EP3261665A1 (en)	2015-02-24	2018-01-03	The United States of America, as represented by The Secretary, Department of Health and Human Services	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
AU2016222830B2 (en)	2015-02-24	2021-02-25	Bioatla Llc	Conditionally active biological proteins
WO2016141387A1 (en)	2015-03-05	2016-09-09	Xencor, Inc.	Modulation of t cells with bispecific antibodies and fc fusions
EP3064507A1 (en)	2015-03-06	2016-09-07	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
EP3683233A1 (en)	2015-03-20	2020-07-22	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Neutralizing antibodies to gp120 and their use
US20180084766A1 (en) *	2015-04-07	2018-03-29	The Children's Medical Center Corporation	Methods and compositions relating to an embryonic stem cell-based tumor model
EP4276116A3 (en)	2015-04-17	2024-01-17	Amgen Research (Munich) GmbH	Bispecific antibody constructs for cdh3 and cd3
JP6746845B2 (ja)	2015-04-22	2020-08-26	イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ，Ｉｎｃ．	循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け
WO2016170102A1 (en)	2015-04-22	2016-10-27	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
CN107847559B (zh)	2015-05-13	2022-07-01	埃博灵克斯股份有限公司	基于cd3反应性的t细胞募集多肽
ES2754427T3 (es)	2015-05-13	2020-04-17	Ablynx Nv	Polipéptidos de reclutamiento de células T basados en la reactividad de TCR alfa/beta
MX2017015380A (es)	2015-05-29	2018-03-28	Amphivena Therapeutics Inc	Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33.
WO2016196975A1 (en)	2015-06-03	2016-12-08	The United States Of America, As Represented By The Secretary Department Of Health & Human Services	Neutralizing antibodies to hiv-1 env and their use
US10195175B2 (en)	2015-06-25	2019-02-05	Immunomedics, Inc.	Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN106349391A (zh) *	2015-07-17	2017-01-25	中国科学院深圳先进技术研究院	Hbv特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环dna及应用
TWI793062B (zh)	2015-07-31	2023-02-21	德商安美基研究（慕尼黑）公司	Ｄｌｌ３及ｃｄ３抗體構築體
TWI717375B (zh)	2015-07-31	2021-02-01	德商安美基研究（慕尼黑）公司	Ｃｄ７０及ｃｄ３抗體構築體
TWI744242B (zh)	2015-07-31	2021-11-01	德商安美基研究（慕尼黑）公司	Egfrviii及cd3抗體構築體
TWI829617B (zh)	2015-07-31	2024-01-21	德商安美基研究（慕尼黑）公司	Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh)	2015-07-31	2023-03-21	德商安美基研究（慕尼黑）公司	Ｍｓｌｎ及ｃｄ３抗體構築體
JO3620B1 (ar)	2015-08-05	2020-08-27	Amgen Res Munich Gmbh	مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
KR20180038560A (ko)	2015-08-28	2018-04-16	아뮤닉스 오퍼레이팅 인코포레이티드	키메라 폴리펩티드 조립체와 이의 제조 및 사용 방법
US20170073399A1 (en)	2015-09-11	2017-03-16	Alexion Pharmaceuticals, Inc.	Recombinant glycosylated eculizumab and eculizumab variants
MA44909A (fr)	2015-09-15	2018-07-25	Acerta Pharma Bv	Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
AR106188A1 (es)	2015-10-01	2017-12-20	Hoffmann La Roche	Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3356407B1 (en)	2015-10-02	2021-11-03	F. Hoffmann-La Roche AG	Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
WO2017062748A1 (en)	2015-10-07	2017-04-13	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017062649A1 (en)	2015-10-07	2017-04-13	Alexion Pharmaceuticals, Inc.	A method for treating age-related macular degeneration in a patient
CN108473555B (zh)	2015-11-02	2022-10-25	生物蛋白有限公司	条件活性多肽
EP4011911A1 (en)	2015-11-03	2022-06-15	The United States of America as represented by The Secretary Department of Health and Human Services	Neutralizing antibodies to hiv-1 gp41 and their use
CN105296421B (zh) *	2015-11-24	2019-01-29	高岱清	一种双特异性抗体活化的t细胞及制备方法与应用
RU2651776C2 (ru) *	2015-12-01	2018-04-23	Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум")	Биспецифические антитела против cd3*cd19
KR20180085800A (ko)	2015-12-07	2018-07-27	젠코어 인코포레이티드	Cd3 및 psma에 결합하는 이종이합체성 항체
SI3386997T1 (sl)	2015-12-09	2021-11-30	Medizinische Universitaet Wien	Spojine platine s funkcionalnimi monomaleimidi za zdravljenje raka
TW202208440A (zh)	2015-12-14	2022-03-01	美商宏觀基因股份有限公司	對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
MD3411402T2 (ro)	2016-02-03	2022-05-31	Amgen Res Munich Gmbh	Constructe de anticorpi bispecifici BCMA și CD3 de angajare a celulei T
CR20180418A (es)	2016-02-03	2019-01-15	Amgen Res Munich Gmbh	Contructos de anticuerpo biespecpificos para psma y cd3 que se ligan a células t
EA039859B1 (ru)	2016-02-03	2022-03-21	Эмджен Рисерч (Мюник) Гмбх	Биспецифические конструкты антител, связывающие egfrviii и cd3
US20170224837A1 (en)	2016-02-10	2017-08-10	Immunomedics, Inc.	Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
JP2019508496A (ja)	2016-02-15	2019-03-28	チェム−フォルシュングスツェントルンフュルモレクラーレメディツィンゲゼルシャフトミットベシュレンクテルハフツング	癌の治療法のためのｔａｆ１阻害剤
EP3216458A1 (en)	2016-03-07	2017-09-13	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Modified vascular endothelial growth factor a (vegf-a) and its medical use
AU2017244108B2 (en)	2016-03-29	2021-03-18	University Of Southern California	Chimeric antigen receptors targeting cancer
WO2017167350A1 (en) *	2016-03-30	2017-10-05	Horst Lindhofer	Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract
KR20180133442A (ko) *	2016-04-13	2018-12-14	비비아 바이오테크 에스.엘.	생체외 bite 활성화된 t 세포
WO2017181143A1 (en)	2016-04-15	2017-10-19	Generon (Shanghai) Corporation, Ltd.	Use of il-22 in treating necrotizing enterocolitis
JOP20170091B1 (ar)	2016-04-19	2021-08-17	Amgen Res Munich Gmbh	إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
AU2017257254B2 (en)	2016-04-27	2022-02-24	Immunomedics, Inc.	Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
WO2017192589A1 (en)	2016-05-02	2017-11-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to influenza ha and their use and identification
CN105906720A (zh) *	2016-05-16	2016-08-31	武汉汉密顿生物科技股份有限公司	靶向性嵌合抗原受体修饰的免疫细胞及其制备方法和应用
MA45255A (fr)	2016-06-14	2019-04-17	Xencor Inc	Anticorps inhibiteurs de points de contrôle bispécifiques
US10669338B2 (en)	2016-06-17	2020-06-02	Immunomedics, Inc.	Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
AU2017290086A1 (en)	2016-06-28	2019-01-24	Xencor, Inc.	Heterodimeric antibodies that bind somatostatin receptor 2
AU2017290828A1 (en)	2016-06-30	2019-01-24	Virogin Biotech Canada Ltd	Pseudotyped oncolytic viral delivery of therapeutic polypeptides
TWI790206B (zh)	2016-07-18	2023-01-21	法商賽諾菲公司	特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
CN109715650B (zh)	2016-07-26	2024-03-08	生物马林药物股份有限公司	新颖腺相关病毒衣壳蛋白
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
TW201825674A (zh)	2016-09-09	2018-07-16	美商艾斯合顧問有限公司	表現雙特異性接合分子的溶瘤病毒
US20190307799A1 (en)	2016-09-23	2019-10-10	The Regents Of The University Of Michigan	Engineered lymphocytes
SG11201903302UA (en)	2016-10-14	2019-05-30	Xencor Inc	Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
WO2018075758A1 (en)	2016-10-19	2018-04-26	Alexion Pharmaceuticals, Inc.	A method of quantitating unbound c5 in a sample
AU2017359288A1 (en)	2016-11-14	2019-05-30	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Combination of a BRD4 inhibitor and an antifolate for the therapy of cancer
JP7222888B2 (ja)	2016-11-16	2023-02-15	アブリンクスエン．ヴェー．	Ｃｄ１２３及びｔｃｒアルファ／ベータに結合することが可能なｔ細胞動員ポリペプチド
EP3556772A4 (en) *	2016-12-13	2020-09-09	Carsgen Therapeutics Ltd	HUMANIZED ANTI-CD19 ANTIBODY AND TARGETING IMMUNE EFFICIENT CELL CD19
CN108264557B (zh) *	2016-12-30	2021-08-24	惠和生物技术(上海)有限公司	一种结合cd3和t细胞负共刺激分子的双功能分子及其应用
CN108264566B (zh) *	2016-12-30	2021-05-14	惠和生物技术(上海)有限公司	一种融合抗cd3抗体结构域和t细胞正共刺激分子配体的双特异性分子及其应用
JOP20190189A1 (ar)	2017-02-02	2019-08-01	Amgen Res Munich Gmbh	تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
WO2018148445A1 (en)	2017-02-08	2018-08-16	Adimab, Llc	Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
WO2018148660A1 (en)	2017-02-10	2018-08-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2018152496A1 (en)	2017-02-17	2018-08-23	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Compositions and methods for the diagnosis and treatment of zika virus infection
KR20240060739A (ko)	2017-02-20	2024-05-08	드래곤플라이 쎄라퓨틱스, 인크.	Her2, nkg2d 및 cd16에 결합하는 단백질
US11459394B2 (en)	2017-02-24	2022-10-04	Macrogenics, Inc.	Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US10918734B2 (en)	2017-03-27	2021-02-16	Immunomedics, Inc.	Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
CN108659112B (zh) *	2017-03-30	2021-01-26	上海市同济医院	一种非对称双特异性抗体
US10799597B2 (en)	2017-04-03	2020-10-13	Immunomedics, Inc.	Subcutaneous administration of antibody-drug conjugates for cancer therapy
EP4230649A3 (en)	2017-04-25	2023-10-25	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
CA3059820A1 (en)	2017-04-26	2018-11-01	Eureka Therapeutics, Inc.	Constructs specifically recognizing glypican 3 and uses thereof
CN110913904A (zh)	2017-05-05	2020-03-24	美国安进公司	用于改善的储存和施用的包含双特异性抗体构建体的药物组合物
WO2018224441A1 (en)	2017-06-05	2018-12-13	Numab Innovation Ag	Novel anti-cd3 antibodies
EP3645048A4 (en) *	2017-06-25	2021-06-16	Systimmune, Inc.	MULTISPECIFIC ANTIBODIES AND THE METHOD OF MANUFACTURING AND USING THEREOF
JP2020529832A (ja)	2017-06-30	2020-10-15	ゼンコアインコーポレイテッド	ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
EP3655430A1 (en)	2017-07-19	2020-05-27	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
CN111164100B (zh)	2017-08-03	2024-03-12	美国安进公司	白介素-21突变蛋白和治疗方法
AU2018328291B2 (en)	2017-09-08	2022-10-27	Takeda Pharmaceutical Company Limited	Constrained conditionally activated binding proteins
JP7150823B2 (ja)	2017-09-08	2022-10-11	アムジエン・インコーポレーテツド	ＫＲａｓＧ１２Ｃの阻害剤及びそれを使用する方法
MA50239A (fr)	2017-09-15	2020-07-22	Amgen Inc	Procédé de formulation pharmaceutique lyophilisée d'une protéine thérapeutique
JP2020536967A (ja)	2017-10-12	2020-12-17	イミュノウェイクインコーポレイテッド	Ｖｅｇｆｒ−抗体軽鎖融合タンパク質
JP2020536923A (ja)	2017-10-13	2020-12-17	メルク・シャープ・エンド・ドーム・コーポレイション	びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法
SG11202002384VA (en)	2017-10-14	2020-04-29	Cytomx Therapeutics Inc	Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CN107739410B (zh) *	2017-10-18	2021-07-30	南京鼓楼医院	CD3单链抗体-iRGD融合蛋白、制备及其作为抗肿瘤药物的应用
SG11202002590VA (en)	2017-11-02	2020-04-29	Bayer Ag	Bispecific antibodies binding alk-1 and bmpr-2
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3082383A1 (en)	2017-11-08	2019-05-16	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US20210163592A1 (en)	2017-12-11	2021-06-03	Amgen Inc	Continuous manufacturing process for bispecific antibody products
CA3085432A1 (en)	2017-12-12	2019-06-20	Macrogenics Inc.	Bispecific cd16-binding molecules and their use in the treatment of disease
WO2019125732A1 (en)	2017-12-19	2019-06-27	Xencor, Inc.	Engineered il-2 fc fusion proteins
UY38041A (es)	2017-12-29	2019-06-28	Amgen Inc	Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
EP3731850A4 (en)	2017-12-29	2021-12-01	Oncorus, Inc.	ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
EP3724223A1 (en)	2018-01-02	2020-10-21	The United States of America, as represented by The Secretary, Department of Health and Human Services	Neutralizing antibodies to ebola virus glycoprotein and their use
CN107987169B (zh) *	2018-01-05	2021-10-08	阿思科力(苏州)生物科技有限公司	一种以ROBO1为靶点的双特异性抗体scFv及其制备和应用
CR20210319A (es)	2018-01-12	2021-07-27	Amgen Inc	ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330)
CA3237846A1 (en)	2018-02-08	2019-08-15	Dragonfly Therapeutics, Inc.	Antibody variable domains targeting the nkg2d receptor
EP3752196A4 (en)	2018-02-15	2022-03-23	MacroGenics, Inc.	VARIANT DOMAINS OF CD3 BINDING AND THEIR USE IN MULTITHERAPIES FOR THE TREATMENT OF A DISEASE
CN111971299A (zh)	2018-02-21	2020-11-20	美国政府(由卫生和人类服务部的部长所代表)	HIV-1 Env的中和抗体及其用途
KR20210028140A (ko)	2018-03-02	2021-03-11	씨디알-라이프 아게	삼중특이성 항원 결합 단백질
JP7154634B2 (ja) *	2018-03-13	2022-10-18	国立大学法人大阪大学	腫瘍免疫賦活剤
WO2019183094A1 (en)	2018-03-19	2019-09-26	The Regents Of The University Of Michigan	Compositions and methods for t-cell and cytokine activation
CA3096052A1 (en)	2018-04-04	2019-10-10	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
CN112437777A (zh)	2018-04-18	2021-03-02	Xencor股份有限公司	包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
US11524991B2 (en)	2018-04-18	2022-12-13	Xencor, Inc.	PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
WO2019207051A1 (en)	2018-04-25	2019-10-31	Università Degli Studi Di Torino	Medical use of combinations of non-natural semaphorins 3 and antimetabolites
US20210171610A1 (en)	2018-05-02	2021-06-10	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
SG11202010830WA (en)	2018-05-09	2020-11-27	Biomarin Pharm Inc	Methods of treating phenylketonuria
TW202005978A (zh)	2018-05-14	2020-02-01	美商拜奧馬林製藥公司	新穎肝靶向腺相關病毒載體
US20220403001A1 (en)	2018-06-12	2022-12-22	Obsidian Therapeutics, Inc.	Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2020010079A2 (en)	2018-07-02	2020-01-09	Amgen Inc.	Anti-steap1 antigen-binding protein
CN112771075A (zh)	2018-07-30	2021-05-07	安进研发（慕尼黑）股份有限公司	结合至cd33和cd3的双特异性抗体构建体的延长施用
JP2021532073A (ja)	2018-07-31	2021-11-25	アムジェンリサーチ（ミュニック）ゲゼルシャフトミットベシュレンクテルハフツング	Ｂｃｍａ−ｃｄ３二重特異性抗体のための投与レジメン
UY38326A (es)	2018-08-03	2020-01-31	Amgen Inc	Constructos de anticuerpos para cldn18.2 y cd3
AU2019331024A1 (en)	2018-08-31	2021-03-18	Regeneron Pharmaceuticals, Inc.	Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
US11066476B2 (en)	2018-09-14	2021-07-20	Shanghai tongji hospital	Asymmetric bispecific antibody
CN110590955B (zh) *	2018-09-17	2021-05-18	北京盛诺基医药科技股份有限公司	一种双特异性抗体
AU2019347710A1 (en)	2018-09-24	2021-02-04	Amgen Inc.	Interventional dosing systems and methods
US11505614B2 (en)	2018-09-28	2022-11-22	Amgen Inc.	Antibodies binding to soluble BCMA
CA3115096A1 (en)	2018-10-03	2020-04-09	Xencor, Inc.	Il-12 heterodimeric fc-fusion proteins
CA3114802A1 (en)	2018-10-11	2020-04-16	Amgen Inc.	Downstream processing of bispecific antibody constructs
CA3115296A1 (en)	2018-10-23	2020-04-30	Amgen Inc.	Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions
SG11202104900SA (en)	2018-11-20	2021-06-29	Univ Cornell	Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
WO2020132214A2 (en)	2018-12-20	2020-06-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
TW202043253A (zh)	2019-01-28	2020-12-01	美商安進公司	藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
US20220137010A1 (en)	2019-02-20	2022-05-05	Amgen Inc.	Methods of determining protein stability
EP3930850A1 (en)	2019-03-01	2022-01-05	Xencor, Inc.	Heterodimeric antibodies that bind enpp3 and cd3
EP3934762A1 (en)	2019-03-05	2022-01-12	Takeda Pharmaceutical Company Limited	Constrained conditionally activated binding proteins
US20220187398A1 (en)	2019-03-27	2022-06-16	Amgen Inc.	Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
EP3962948A1 (en)	2019-04-30	2022-03-09	Amgen Research (Munich) GmbH	Means and methods of treating burkitt lymphoma or leukemia
WO2020227228A2 (en)	2019-05-03	2020-11-12	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
US20230085439A1 (en)	2019-05-21	2023-03-16	University Of Georgia Research Foundation, Inc.	Antibodies that bind human metapneumovirus fusion protein and their use
MX2021015045A (es)	2019-06-07	2022-03-17	Amgen Inc	Construcciones de unión biespecíficas.
TW202045711A (zh)	2019-06-13	2020-12-16	美商安進公司	生物製品製造中基於生物量之自動灌注控制
WO2021003297A1 (en)	2019-07-02	2021-01-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind egfrviii and their use
CN110623921B (zh) *	2019-08-15	2020-10-30	北京东方百泰生物科技股份有限公司	一种抗cd3和抗cd19的双特异性抗体注射制剂
RU2738802C1 (ru)	2019-08-21	2020-12-17	Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум"	Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
GB201912681D0 (en)	2019-09-04	2019-10-16	Eth Zuerich	Bispecific binding agent that binds to cd117/c-kit and cd3
AU2020345787A1 (en)	2019-09-10	2022-03-24	Amgen Inc.	Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
WO2021064189A2 (en)	2019-10-02	2021-04-08	Domain Therapeutics	Prostaglandin e2 (pge2) ep4 receptor antagonists
US20230124700A1 (en)	2019-10-16	2023-04-20	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
EP3808741A1 (en)	2019-10-16	2021-04-21	CeMM - Forschungszentrum für Molekulare Medizin GmbH	Compounds for targeted degradation of carrier proteins and uses thereof
WO2021074418A1 (en)	2019-10-16	2021-04-22	Cemm - Forschungszentrum Für Molekulare Medizin Gmbh	Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
US20220389099A1 (en)	2019-11-04	2022-12-08	Amgen Inc.	Methods for treating leukemia
EP3819312A1 (en)	2019-11-10	2021-05-12	Amgen, Inc	Dosing regimen for anti-dll3 agents
EP3819007A1 (en)	2019-11-11	2021-05-12	Amgen Research (Munich) GmbH	Dosing regimen for anti-bcma agents
EP4058485A1 (en)	2019-11-13	2022-09-21	Amgen Inc.	Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
EP4093771A1 (en)	2020-01-22	2022-11-30	Amgen Research (Munich) GmbH	Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
IL295129A (en)	2020-01-30	2022-09-01	Umoja Biopharma Inc	Bispecific transduction enhancer
WO2021158469A1 (en)	2020-02-03	2021-08-12	Amgen Inc.	Multivariate bracketing approach for sterile filter validation
TW202140561A (zh)	2020-02-14	2021-11-01	日商協和麒麟股份有限公司	與cd3結合之雙特異性抗體
CN115066440A (zh)	2020-02-28	2022-09-16	上海复宏汉霖生物技术股份有限公司	抗cd137构建体及其用途
JP2023516941A (ja)	2020-02-28	2023-04-21	上海復宏漢霖生物技術股▲フン▼有限公司	抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
CA3173981A1 (en)	2020-03-10	2021-09-16	Massachusetts Institute Of Technology	Compositions and methods for immunotherapy of npm1c-positive cancer
EP4118113A1 (en)	2020-03-12	2023-01-18	Amgen Inc.	Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
CN115427454A (zh)	2020-03-19	2022-12-02	安进公司	针对粘蛋白17的抗体及其用途
US11919956B2 (en)	2020-05-14	2024-03-05	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP4153633A1 (en)	2020-05-19	2023-03-29	Amgen Inc.	Mageb2 binding constructs
EP4157874A2 (en)	2020-05-29	2023-04-05	Amgen Inc.	Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
AU2021283345A1 (en)	2020-06-02	2023-02-02	Dynamicure Biotechnology Llc	Anti-CD93 constructs and uses thereof
CN116529260A (zh)	2020-06-02	2023-08-01	当康生物技术有限责任公司	抗cd93构建体及其用途
US20230203198A1 (en)	2020-06-04	2023-06-29	Amgen Inc.	Bispecific binding constructs
AU2021315665A1 (en)	2020-07-29	2023-03-16	Dynamicure Biotechnology Llc	Anti-CD93 constructs and uses thereof
IL300666A (en)	2020-08-19	2023-04-01	Xencor Inc	ANTI–CD28 COMPOSITIONS
AU2021331170A1 (en)	2020-08-27	2023-03-23	Juntendo Educational Foundation	Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition
MX2023002881A (es)	2020-09-11	2023-04-24	Amgen Inc	Materiales y metodos para reducir la agregacion de proteinas.
WO2022060901A1 (en)	2020-09-16	2022-03-24	Amgen Inc.	Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
WO2022060878A1 (en)	2020-09-16	2022-03-24	Amgen Inc.	Methods for treating prostate cancer
CA3194868A1 (en)	2020-10-16	2022-04-21	Georg Winter	Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
KR20230104229A (ko)	2020-11-06	2023-07-07	암젠 인크	Cd3에 결합하는 폴리펩티드 구축물
MX2023005343A (es)	2020-11-06	2023-05-22	Amgen Res Munich Gmbh	Construcciones polipeptidicas que se unen selectivamente a cldn6 y cd3.
CA3200317A1 (en)	2020-11-06	2022-05-12	Amgen Inc.	Multitargeting bispecific antigen-binding molecules of increased selectivity
CA3198064A1 (en)	2020-11-06	2022-05-12	Amgen Inc.	Antigen binding domain with reduced clipping rate
TW202233682A (zh)	2020-11-10	2022-09-01	美商安進公司	用於投與ＢＣＭＡｘＣＤ３結合分子之方法
CN116783217A (zh)	2020-12-03	2023-09-19	安进公司	具有多个结合结构域的免疫球蛋白构建体
WO2022132904A1 (en)	2020-12-17	2022-06-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies targeting sars-cov-2
CA3203141A1 (en)	2020-12-18	2022-06-23	Ablynx Nv	T cell recruiting polypeptides based on tcr alpha/beta reactivity
KR20230147092A (ko)	2021-01-22	2023-10-20	바이원큐어 테라퓨틱스, 인크.	항-her-2/trop-2 작제물 및 이의 용도
JP2024506831A (ja)	2021-01-28	2024-02-15	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	サイトカイン放出症候群を治療するための組成物及び方法
JP2024506315A (ja)	2021-02-09	2024-02-13	ザユナイテッドステイツオブアメリカアズリプリゼンテッドバイザセクレタリー、デパートメントオブヘルスアンドヒューマンサービシーズ	コロナウイルスのスパイクタンパク質を標的とする抗体
CA3210753A1 (en)	2021-02-09	2022-08-18	University Of Georgia Research Foundation, Inc.	Human monoclonal antibodies against pneumococcal antigens
TW202241494A (zh)	2021-02-10	2022-11-01	大陸商同潤生物醫藥(上海)有限公司	治療腫瘤的方法和組合
WO2022192403A1 (en)	2021-03-09	2022-09-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and cldn6
EP4304755A1 (en)	2021-03-10	2024-01-17	Amgen Inc.	Parallel chromatography systems and methods
EP4305065A1 (en)	2021-03-10	2024-01-17	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and gpc3
WO2022192504A1 (en)	2021-03-10	2022-09-15	Amgen Inc.	Methods for purification of recombinant proteins
EP4314049A1 (en)	2021-03-25	2024-02-07	Dynamicure Biotechnology LLC	Anti-igfbp7 constructs and uses thereof
CN112794916B (zh) *	2021-04-08	2021-08-10	正大天晴药业集团南京顺欣制药有限公司	三特异性抗原结合构建体及构建方法和应用
CA3217180A1 (en)	2021-05-06	2022-11-10	Amgen Research (Munich) Gmbh	Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
EP4355785A1 (en)	2021-06-17	2024-04-24	Amberstone Biosciences, Inc.	Anti-cd3 constructs and uses thereof
AU2022345251A1 (en)	2021-09-17	2024-03-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
CA3235228A1 (en)	2021-10-15	2023-04-20	Amgen Research (Munich) Gmbh	Subcutaneous administration of cd19-binding t cell engagers
TW202326113A (zh)	2021-10-27	2023-07-01	美商安進公司	使用光譜學進行的基於深度學習的預測
EP4180035A1 (en)	2021-11-15	2023-05-17	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Novel beta-lactone inhibitors of hydrolytic enzymes and their medical and non medical uses
WO2023110918A1 (en)	2021-12-14	2023-06-22	Cdr-Life Ag	Dual mhc-targeting t cell engager
WO2023154824A1 (en)	2022-02-10	2023-08-17	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that broadly target coronaviruses
WO2023164474A1 (en)	2022-02-23	2023-08-31	Amgen Inc.	Cancer treatment targeting dll3
WO2023192881A1 (en)	2022-03-28	2023-10-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to hiv-1 env and their use
US20230357446A1 (en)	2022-04-11	2023-11-09	Regeneron Pharmaceuticals, Inc.	Compositions and methods for universal tumor cell killing
WO2023203172A1 (en)	2022-04-20	2023-10-26	Proxygen Gmbh	Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
TW202346368A (zh)	2022-05-12	2023-12-01	德商安美基研究（慕尼黑）公司	具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
WO2023237366A1 (en)	2022-05-27	2023-12-14	Sanofi	Anti-bcma antibodies
WO2023242247A1 (en)	2022-06-14	2023-12-21	Ablynx Nv	Immunoglobulin single variable domains targeting t cell receptor
WO2024030829A1 (en)	2022-08-01	2024-02-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
WO2024054822A1 (en)	2022-09-07	2024-03-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Engineered sars-cov-2 antibodies with increased neutralization breadth
US20240091262A1 (en)	2022-09-14	2024-03-21	Cdr-Life Ag	Mage-a4 peptide dual t cell engagers
WO2024059675A2 (en)	2022-09-14	2024-03-21	Amgen Inc.	Bispecific molecule stabilizing composition
WO2024064826A1 (en)	2022-09-22	2024-03-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2024068944A1 (en)	2022-09-30	2024-04-04	Sanofi	Anti-cd28 antibodies
WO2024077044A1 (en)	2022-10-05	2024-04-11	Amgen Inc.	Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024092033A1 (en)	2022-10-26	2024-05-02	Amgen Inc.	Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5239062A (en) *	1986-03-20	1993-08-24	Dana-Farber Cancer Institute, Inc.	Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
GB8928874D0 (en) *	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
CA2063035A1 (en) *	1991-03-27	1992-09-28	Klaus Karjalainen	Chimaeric antibodies containing the ligand domain of cd4
US5637481A (en) *	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
AU8124694A (en) *	1993-10-29	1995-05-22	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
EP0835134A1 (en)	1995-05-17	1998-04-15	Regents Of The University Of Minnesota	Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies
DE19531348A1 (de) *	1995-08-25	1997-02-27	Gsf Forschungszentrum Umwelt	Antikörper mit zwei oder mehr Spezifitäten zur selektiven Eliminierung von Zellen in vivo
WO1999054440A1 (en) *	1998-04-21	1999-10-28	Micromet Gesellschaft Für Biomedizinische Forschung Mbh	CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
EP1629012B1 (en)	2003-05-31	2018-11-28	Amgen Research (Munich) GmbH	Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders

1999
- 1999-04-21 WO PCT/EP1999/002693 patent/WO1999054440A1/en active IP Right Grant
- 1999-04-21 US US09/673,735 patent/US7112324B1/en not_active Expired - Lifetime
- 1999-04-21 RU RU2000128668/15A patent/RU2228202C2/ru active
- 1999-04-21 EP EP03015037A patent/EP1348715A3/en not_active Withdrawn
- 1999-04-21 ID IDW20001963D patent/ID27512A/id unknown
- 1999-04-21 DE DE69909459T patent/DE69909459T2/de not_active Expired - Lifetime
- 1999-04-21 CN CNB99805240XA patent/CN1302103C/zh not_active Expired - Lifetime
- 1999-04-21 JP JP2000544772A patent/JP4169478B2/ja not_active Expired - Lifetime
- 1999-04-21 SI SI9930335T patent/SI1071752T1/xx unknown
- 1999-04-21 NZ NZ507381A patent/NZ507381A/en not_active IP Right Cessation
- 1999-04-21 HU HU0102535A patent/HU229039B1/hu unknown
- 1999-04-21 DK DK99924816T patent/DK1071752T3/da active
- 1999-04-21 CZ CZ20003889A patent/CZ302070B6/cs not_active IP Right Cessation
- 1999-04-21 AU AU41352/99A patent/AU761587B2/en not_active Expired
- 1999-04-21 PT PT99924816T patent/PT1071752E/pt unknown
- 1999-04-21 AT AT99924816T patent/ATE244758T1/de active
- 1999-04-21 PL PL344016A patent/PL199747B1/pl unknown
- 1999-04-21 KR KR10-2000-7011396A patent/KR100508289B1/ko active Protection Beyond IP Right Term
- 1999-04-21 SK SK1579-2000A patent/SK286683B6/sk not_active IP Right Cessation
- 1999-04-21 TR TR2000/03087T patent/TR200003087T2/xx unknown
- 1999-04-21 BR BRPI9909860A patent/BRPI9909860B8/pt not_active IP Right Cessation
- 1999-04-21 CA CA002326389A patent/CA2326389C/en not_active Expired - Lifetime
- 1999-04-21 ES ES99924816T patent/ES2203141T3/es not_active Expired - Lifetime
- 1999-04-21 IL IL13885799A patent/IL138857A0/xx active IP Right Grant
- 1999-04-21 EP EP99924816A patent/EP1071752B1/en not_active Expired - Lifetime
2000
- 2000-10-04 IL IL138857A patent/IL138857A/en active Protection Beyond IP Right Term
- 2000-10-20 ZA ZA200005866A patent/ZA200005866B/en unknown
- 2000-10-20 NO NO20005296A patent/NO326523B1/no not_active IP Right Cessation
- 2000-10-20 HR HR20000714A patent/HRP20000714B1/xx not_active IP Right Cessation
- 2000-10-20 CU CU20000223A patent/CU23252B7/es not_active IP Right Cessation
2001
- 2001-12-05 HK HK01108522A patent/HK1037674A1/xx unknown
2006
- 2006-05-05 US US11/418,058 patent/US7575923B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HUP0102535A2 (hu)	2001-10-28
HK1037674A1 (en)	2002-02-15
ES2203141T3 (es)	2004-04-01
IL138857A (en)	2007-08-19
HU229039B1 (en)	2013-07-29
TR200003087T2 (tr)	2001-02-21
IL138857A0 (en)	2001-10-31
SK15792000A3 (sk)	2001-05-10
AU4135299A (en)	1999-11-08
CA2326389C (en)	2007-01-23
ID27512A (id)	2001-04-12
HUP0102535A3 (en)	2005-12-28
PT1071752E (pt)	2003-11-28
WO1999054440A1 (en)	1999-10-28
EP1348715A3 (en)	2003-11-19
RU2228202C2 (ru)	2004-05-10
US7575923B2 (en)	2009-08-18
US20060193852A1 (en)	2006-08-31
EP1071752B1 (en)	2003-07-09
HRP20000714A2 (en)	2001-12-31
BRPI9909860B1 (pt)	2016-05-31
BR9909860A (pt)	2000-12-19
PL199747B1 (pl)	2008-10-31
US7112324B1 (en)	2006-09-26
KR100508289B1 (ko)	2005-08-17
CZ20003889A3 (cs)	2001-03-14
HRP20000714B1 (en)	2006-03-31
SI1071752T1 (en)	2003-12-31
CZ302070B6 (cs)	2010-09-29
SK286683B6 (sk)	2009-03-05
NO20005296L (no)	2000-12-13
EP1071752A1 (en)	2001-01-31
BRPI9909860B8 (pt)	2021-05-25
EP1348715A2 (en)	2003-10-01
PL344016A1 (en)	2001-09-24
KR20010071150A (ko)	2001-07-28
NZ507381A (en)	2003-12-19
CA2326389A1 (en)	1999-10-28
JP4169478B2 (ja)	2008-10-22
DE69909459D1 (de)	2003-08-14
DE69909459T2 (de)	2004-05-27
JP2002512020A (ja)	2002-04-23
NO20005296D0 (no)	2000-10-20
ATE244758T1 (de)	2003-07-15
CN1299410A (zh)	2001-06-13
AU761587B2 (en)	2003-06-05
DK1071752T3 (da)	2003-10-20
ZA200005866B (en)	2001-04-18
CN1302103C (zh)	2007-02-28
CU23252B7 (es)	2007-12-17

Legal Events

Date	Code	Title	Description
2015-11-16	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: AMGEN RESEARCH (MUNICH) GMBH, DE
2019-05-13	MK1K	Patent expired

Publication	Publication Date	Title
NO326523B1 (no)	2008-12-22	CD19xCD3-spesifikke polypeptid, vektor, celle, sammensetning, fremgangsmate for fremstilling samt anvendelse av nevnte polypeptid eller et polynukleotid som koder for nevnte polypeptid.
CA2555503C (en)	2018-03-27	Humanized anti-cd3 bispecific binding molecules having reduced immunogenicity, uses and compositions relating thereto
TWI646107B (zh)	2019-01-01	Ｂｃｍａ及ｃｄ３之結合分子
EP1100830B1 (en)	2003-10-01	Heterominibodies
US8076459B2 (en)	2011-12-13	Multispecfic deimmunized CD3-binders
RU2252786C2 (ru)	2005-05-27	Конструкции антител и хемокинов и их применение при иммунологических нарушениях
MXPA00010245A (en)	2002-05-09	CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
BG65066B1 (bg)	2007-01-31	CD19 x CD3 СПЕЦИФИЧНИ ПОЛИПЕПТИДИ И ТЯХНОТО ИЗПОЛЗВАНЕ